ABSTRACT: The discovery of somatic mutations in cancer-related genes has been applied to understand the genetic basis of cancer. Here we report somatic mutations of two tumor suppressor genes: LKB1 (exons 1, 4, and 8) and TP16 (CDKN2A) (exons 1 and 2); and two oncogenes: epidermal growth factor receptor EGFR (exons 18-21) and KRAS (exon 2) in 97 lung adenocarcinoma tissues in a cohort from the Kujukuri coast area of Chiba, Japan. In the LKB1 gene, only F354L substitutions were observed in 14 of the 97 tissue samples (14.4%). In the TP16 gene, only two deletions were observed in contrast to previous reports. On the other hand, the EGFR gene was highly mutated (38.1%) and mainly L858R substitutions occurred (23.7%) as well as insertions and deletions. In the KRAS gene, 10 substitutions at codon 12 were observed (10.3%). Co-occurrence of EGFR and KRAS somatic mutations was identified in one patient, those of EGFR and LKB1 were in three patients, and those of KRAS and LKB1 were in four patients. The lower rates of LKB1, TP16, and KRAS somatic mutations in lung adenocarcinomas are characteristic of the Kujukuri cohort as compared to Caucasians.
Introduction
The LKB1 tumor suppressor gene, which encodes serinethreonine kinase 11 (STK11), has been shown to regulate cell cycle progression, apoptosis, and cell polarity (1) . Previous reports have suggested a LKB1 somatic mutation rate as high as 30% in non-small cell lung carcinoma (NSCLC) tumors derived from Caucasian patients (2,3), while being infrequent in NSCLC Asian patients (3%) (4) . Another review (5) reported that LKB1 somatic mutations were observed in 20.18% of lung adenocarcinoma by analyzing the Catalog of Somatic Mutations in Cancer (COSMIC) (6) , a large-scale database curated by the Wellcome Trust Sanger Institute. The TP16 gene (CDKN2A, cyclin-dependent kinase inhibitor 2A) is also a tumor suppressor gene and has been reported to show a high rate of deletions as a major type of somatic mutation in cancer, consisting of 24.57% of lung adenocarcinomas in the COSMIC database (5) . In contrast to these tumor suppressor genes, EGFR and KRAS oncogenes play a central role in tumorigenesis. The tyrosine kinase activity of EGFR phosphorylates tyrosine residues of target proteins, including KRAS, to initiate multiple signaling pathways resulting in cell proliferation, migration, metastasis, resistance to apoptosis, and angiogenesis (7, 8) . Smallmolecule inhibitors of EGFR tyrosine kinase activity (TKIs) such as gefitinib and erlotinib provide a good concept for anticancer drugs. However, clinical trials have revealed significant variability in the TKI response depending on EGFR and KRAS gene mutations (9) . Interestingly, somatic EGFR and KRAS gene mutations, which are upstream and downstream of the RAS pathway, respectively, have been reported to be mutually exclusive. Thus, concurrent EGFR and KRAS mutations have been very rare (5) .
Lung adenocarcinoma is the most common form of lung cancer, which has an average 5-year survival rate of 15%, mainly because of late-stage detection and paucity of late-stage treatment options (10, 11) . To determine the genetic basis of lung adenocarcinoma in a cohort from the Kujukuri coast area in Chiba prefecture, Japan, we analyzed exons 1, 4, and 8 of LKB1, exons 1 and 2 of TP16 which includes almost the entire sequence of the protein coding region, exons 18-21 of EGFR, and exon 1 of KRAS, according to the histogram of somatic mutations in LKB1, TP16, EGFR and KRAS from the COSMIC database (6).
Materials and Methods

Patients
Primary tumor samples from patients with lung adeno- 
DNA extraction and sequencing analysis
Genomic DNA extraction was performed using a simple 96-well plate based DNA extraction. A few milligrams of the frozen specimen was digested with Proteinase K at 55°C for 2 h in 100 μL of extraction buffer (10 mM TrisHCl pH 7.5, 5 mM EDTA, 0.5% Tween 20) followed by heat inactivation at 95°C for 10 min. The preparation was centrifuged at 3000 × g for 15 min, and 2-5 μL of the supernatant was used as a PCR template.
Mutations were detected using PCR-based direct sequencing of three LKB1 exons (exons 1, 4, 8), two TP16 exons (exons 1, 2), four EGFR exons (exons 18-21), and exon 1 of the KRAS gene. The primers for PCR amplification and sequencing analysis are shown in Table 1 .
PCR amplification was done in 50 μL reactions containing 0.2 μM of each primer pair and 0.25 units of Pfu DNA polymerase (Celestar-Lexico Sciences, Chiba, Japan).
LKB1 exons were amplified by initial denaturation at 94°C for 5 min followed by 40 cycles of 10 sec at 98°C, 30 sec at 68°C, and a 1 min final extension at 72°C. TP16 exons were amplified by initial denaturation at 94°C for 5 min followed by 40 cycles of 10 sec at 98°C, 30 sec at 65°C, 30 sec at 72°C, and a 1 min final extension at 72°C. TP16 exon 2 amplification was performed with 5% of DMSO. EGFR exons were amplified by initial denaturation at 94°C for 1 min followed by 35 cycles of 5 sec at 98°C, 30 sec at 65°C, 1 min at 72°C, and a final extension at 72°C for 1 min. The exon 1 region of KRAS was amplified by initial denaturation at 94°C for 1 min followed by 40 cycles at 98°C for 5 sec, 50°C for 30 sec, and 72°C for 30 sec, and a final extension at 72°C for 5 min.
The PCR products were purified using a GFX96 PCR purification kit (GE Healthcare Life Sciences, Little Chalfont, UK) and sequenced directly using a 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA) with 1 μM of each sequencing primer.
Several samples that were difficult to determine the mutation status by the direct sequencing method were cloned into pUC118 before sequencing.
Results
Somatic mutations in LKB1, TP16, EGFR, and KRAS genes observed in the cohort from the Kujukuri coast area of Chiba prefecture are summarized in Table 2 . The sequence chromatograms are shown in Figures 1, 2 , and 3 for single nucleotide substitutions in LKB1, EGFR, and KRAS; two TP16 deletions; and EGFR deletions and insertions, respectively. 
Sequencing primer sequences 
The two right columns show the numbers related to gender. 
LKB1 and TP16 mutations
We analyzed the sequence of exons 1, 4, and 8 of the LKB1 gene and the sequence of the TP16 gene (exons 1 and 2). Of the 97 lung adenocarcinoma tissue samples, only 14 samples (14.4%) were observed to contain F354L substitutions in exon 8 of the LKB1 gene, of which two samples showed biallelic mutations. Figure 1A shows the three types of LKB1 sequences observed in chromatograms: wild type, hetero F354L mutation, and biallelic (homo) F354L mutation. On the other hand, only 2 of the 97 tissue samples (2.1%) showed deletions in exon 2 of the TP16 gene (cytosine deletion at 549 changed the amino acid sequence after 82Val; and the deletion from 666 to 673 changed the amino acid sequence after 121Leu; the numbers of nucleotides and residues are from NM_000077.4 and NP_000068.1 in the NCBI database), as shown in Figures 2A and 2B. 
EGFR and KRAS mutations
The major somatic mutations of the EGFR gene observed in the cohort were L858R substitutions at 27 exon 21, as shown in the Figure 1B chromatogram. There were 23 samples of the 97 tissue samples (23.7%) that showed only this substitution and four samples that showed other types of mutations in addition to this substitution (Table 2 ). Another major mutation was the 746-ELREA-750 deletion at exon 19 that was observed in 7 samples (7.2%). The sequencing result chromatogram showed this deletion in Figure 3A . Figures 3B and 3C showed the sequencing results of insertion mutations. Figure 3B showed the insertion of three amino acids YNP between 772Pro and 773His in exon 20, and the histidine residue was substituted by Tyr. Figure 3C showed the insertion of three amino acids SVD between 770Asp and 771Asn in exon 20. The other mutations observed are summarized in Table  2 . In total, 37 of 97 samples (38.1%) displayed somatic mutations in the EGFR gene.
The somatic mutations observed in the KRAS gene were only substitutions at codon 12 of amino acid residue Gly to Asp (3 samples), to Val (1 sample), to Ala (2 samples), and to Cys (4 samples). A total of 10 samples showed somatic mutations in KRAS (10.3%). Figure 1C shows the sequences of the somatic mutations at KRAS codon 12 on chromatograms. 
Concurrency of mutations
The concurrent EGFR and KRAS mutations have been reported to be very rare (5), meaning the occurrence of those mutations were mutually exclusive in lung adenocarcinoma. We observed that only one of the 97 tissue samples harbored the concurrent EGFR and KRAS mutations. In contrast, co-occurrence of EGFR and LKB1 mutations were observed in three samples, while co-occurrence of KRAS and LKB1 mutations were observed in four samples.
Discussion
We analyzed somatic mutations in tumor suppressor genes LKB1 and TP16, and in oncogenes EGFR and KRAS, using 97 lung adenocarcinoma tissue samples in a cohort from the Kujukuri coast area of Chiba prefecture, Japan. Compared with the review paper that analyzed the COSMIC database (5), we showed the rate of TP16 somatic mutations in the Kujukuri cohort to be very small (2.1%), while the COSMIC database showed a 24.57% mutation rate. The LKB1 mutation rate was 14.4% from our observations, while that of the COSMIC database was 20.18%. In particular, only F354L substitutions in the LKB1 gene were observed in the Kujukuri cohort.
As for EGFR, the somatic mutation rate was 38.1% from our observations, which is a little bit higher than the rate from the COSMIC database (35.85%). KRAS also showed a lower somatic mutation rate in the Kujukuri cohort (10.3%) than that from the COSMIC database (23.02%). The lower rates of somatic mutations for LKB1, TP16, and KRAS genes in lung adenocarcinomas are characteristic of the Kujukuri cohort.
EGFR mutations have been more commonly found in tumors from patients who never smoked cigarettes (12) , while KRAS mutations have been present in those with significant tobacco exposure (9, 13) . Unfortunately, we could not follow the history of smoking or nonsmoking patients from clinical records of the cohort, except for the 11 patients who were never-smokers. Among the 11 patients, we found four EGFR mutations (36.3% = 4/11) that included three L858R substitutions and one insertion, and a single KRAS mutation (9.1% = 1/11). The percentages of EGFR and KRAS mutations in the 11 never-smoking patients were not significantly different from those in the remaining 86 patients (EGFR: 38.3% = 33/86, and KRAS: 10.5% = 9/86), suggesting that EGFR and KRAS mutations in the cohort are not associated with tobacco use. Contrary to previous reports describing the association between EGFR mutations and non-smoking history (12) , recent papers have reported no association with smoking or nonsmoking history in Asian patients (14) (15) (16) .
Gender also has been reported to be unconnected with EGFR mutations in Asian patients (14, 15) . We also found no association between gender and any type of EGFR mutations in the cohort. However, focusing on the 746ELREA deletions, 6 out of 7 patients with this type of deletion were male patients. Moreover, we investigated the distribution of mutations in the four genes across different clinicopathological subgroups based on tumor size, clinical stage, and histological subtypes including acinar, papillary, and bronchioloalveolar carcinoma patterns. However, no significant association with clinicopathological subgroups was found (data not shown), which is consistent with a previous report (17) .
One interesting topic in analyzing genetic somatic mutations is the co-occurrence of mutations in two genes. Co-occurrence of EGFR and KRAS mutations, which lie upstream and downstream of the RAS pathway respectively, has been reported to be mutually exclusive (5) . In the review paper that analyzed the COSMIC database (5), the co-occurrence of TP16 and KRAS mutations was reported in pancreatic cancer, lung large cell cancer, colon cancer, kidney tumors, and lung adenocarcinoma. However, in the present study, co-occurrence of TP16 and KRAS mutations was not observed because of the lower mutation rate of TP16 in the Kujukuri cohort. On the other hand, as to LKB1 we co-sequenced LKB1 and KRAS in the 97 lung adenocarcinomas tissue samples, and found four co-occurring mutations in these genes. So, mutations in these genes may not be mutually exclusive and therefore these genes may not be located on the same pathway. Co-occurrence of LKB1 and EGFR mutations was also observed in three samples. Taken together, LKB1 might act separately from the RAS pathway to suppress tumorigenesis. According to the known pathways summarized from the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Figure 4 ) related to the LKB1, TP16, EFGR, and KRAS genes pathways, LKB1 attenuates protein synthesis by inhibiting the mTOR pathway (18) , that is separated from the RAS pathway.
